CHMP recommends label extensions for Afinitor, Enbrel, Cayston and Humira
This article was originally published in Scrip
Executive Summary
The EMA's Committee for Medicinal Products for Human Use has recommended label extensions for four drugs: Novartis' Afinitor (everolimus), Gilead Sciences' Cayston (aztreonam), Pfizer's Enbrel (etanercept) and Abbott's Humira (adalimumab).
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.